Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • WS 3: A Source-Bounded TRPM8 Agonist Overview

    2026-10-18

    WS 3 is described by APExBIO as a potent TRPM8 receptor agonist, with activity reported in recombinant and heterologous cell systems. The available evidence for this overview is the supplier’s WS 3 product page; no identity-matched research paper is available. That distinction is central: the page documents a product identity, selected assay readouts, and vendor-reported potency values, but it does not provide the evidentiary depth of an independently reported pharmacology study.

    1. Documented identity and scientific context

    APExBIO identifies WS 3 by the chemical name N-(6-(4-(3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)ureido)phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide. The listed molecular formula is C28H30F3N7O3, with a molecular weight of 569.58. The product is listed as a solid with a reported purity of 99.41% and is identified as SKU B7223.

    The same page reports that WS 3 is insoluble in water and soluble in ethanol and dimethyl sulfoxide under the supplier’s stated product-characterization conditions. These are material and handling descriptors, not evidence that the compound will produce a particular biological response in a native tissue or organism. APExBIO labels the material for scientific research use rather than diagnostic or medical use; that designation does not independently establish the compound’s pharmacological profile.

    2. Documented mechanism and measurement principle

    TRPM8 is a member of the transient receptor potential ion-channel family. According to the product description, it is permeable to calcium and sodium ions, is activated by cooling agents and cold temperatures, and is predominantly expressed in sensory neurons. In that framework, TRPM8 ion channel activation is an upstream molecular event, whereas a rise in intracellular calcium is a downstream cellular readout.

    The supplier reports EC50 values of 3.7 μM in a mouse recombinant TRPM8 system and 2.2 μM in human TRPM8-expressing HEK cells. An EC50 is conventionally interpreted as the concentration associated with half-maximal response in a particular concentration–response assay. It is therefore a context-dependent potency descriptor, not a universal property independent of species, expression system, assay design, receptor abundance, or response normalization. Because the product description does not provide full concentration–response curves, replicate numbers, uncertainty estimates, or assay comparators, the two values should not be treated as a definitive cross-species ranking.

    APExBIO also reports that WS 3 increases intracellular calcium concentration in HEK293 cells expressing TRPM8. This result is consistent with functional coupling between the expressed channel and a calcium-sensitive measurement. It does not, by itself, establish direct physical binding, prove that calcium is the only relevant ionic contributor, or demonstrate a sensory response in native neurons. That distinction matters for research on the cold sensation signaling pathway: a cell-based calcium signal can support receptor activation while remaining several biological steps removed from neuronal firing, circuit processing, or perception.

    The product page reports activity at human TRPA1 with an EC50 of 120.6 μM, described as lower potency than activity at TRPM8. This provides evidence that the supplier observed a TRPA1-associated assay response at a higher reported concentration, but it does not define a complete selectivity profile. Without matched assay details, maximal-response information, controls, and independent replication, the result should be treated as a documented secondary activity claim rather than proof of physiological TRPA1 involvement.

    3. Interpretation of the supplied properties and scope

    The most defensible conceptual scope for WS 3 is pharmacological activation of TRPM8 in recombinant or heterologous expression systems. In that setting, the reported calcium response provides a functional measurement of calcium influx modulation in HEK293 cells expressing the target. It is not equivalent to evidence from native sensory neurons.

    The supplier characterizes WS 3 as eliciting a strong cooling sensation. The available product information does not identify a human psychophysical study, a native sensory-neuron experiment, or an in vivo comparison that would independently substantiate that statement. Accordingly, WS 3 may be discussed as a reported cooling-associated TRPM8 agonist in product documentation, but the evidence provided here does not establish the magnitude, duration, subjective quality, or physiological relevance of cooling in people.

    Likewise, the product description is relevant to sensory neuron thermosensitivity research only at the level of target biology and conceptual assay interpretation. It does not document effects on neuronal excitability, synaptic signaling, behavior, inflammation, analgesia, or disease phenotypes. Extending the HEK-cell calcium result into any of those domains would go beyond the supplied evidence.

    Claim Reported evidence Proportionate interpretation
    TRPM8 agonism The APExBIO description reports EC50 values of 3.7 μM in mouse recombinant TRPM8 and 2.2 μM in human TRPM8-expressing HEK cells. Supports a vendor-reported concentration-dependent TRPM8 response in the stated systems; it does not independently establish potency across all biological contexts.
    Functional cellular response Increased intracellular calcium was reported in HEK293 cells expressing TRPM8. Supports a downstream calcium-associated response after target expression and compound exposure; it does not alone prove direct binding or native neuronal activation.
    Secondary channel activity Activity at human TRPA1 was reported with an EC50 of 120.6 μM. Indicates a lower-potency response in the stated assay context, but does not establish selectivity, physiological relevance, or a complete off-target profile.
    Cooling sensation The product page describes WS 3 as eliciting a strong cooling sensation. This is a supplier-level characterization; no human sensory outcome or independently reported psychophysical evidence is available here.

    4. Evidence availability and specific boundaries

    For this editorial, no identity-matched research paper is available. The evidence base is therefore limited to commercial product information rather than a peer-reviewed, independently reproducible study. The source does not state sample sizes, replicate structure, uncertainty intervals, statistical tests, full concentration–response parameters, assay controls, or comparator agonists. Their absence from the product description should not be interpreted as proof that such information could not exist elsewhere; it means only that these details cannot support the present assessment.

    Several applicability boundaries follow directly from the reported models:

    • Expression-system boundary: recombinant channels and TRPM8-expressing HEK cells are useful for target-linked measurements but do not reproduce the full molecular environment of sensory neurons.
    • Readout boundary: intracellular calcium is downstream of channel activity and may not capture all relevant ionic, electrical, or signaling consequences.
    • Species and model boundary: the reported mouse recombinant and human HEK values arise from different systems, so their numerical difference cannot be assigned solely to species biology.
    • Selectivity boundary: the reported hTRPA1 value documents an additional assay signal but does not establish whether TRPM8 is the exclusive or dominant target in any native preparation.
    • Provenance boundary: APExBIO is identified here as the supplier. The available information does not document that any independent study used this supplier, a particular lot, or the stated product specification.

    These limitations also constrain comparisons. The supplied information compares WS 3-associated values across TRPM8 systems and reports a separate hTRPA1 value, but it does not provide a head-to-head comparison with another TRPM8 agonist, a cold stimulus, or a validated sensory endpoint. Thus, the evidence supports a narrow mechanism-and-measurement interpretation rather than claims about relative performance among cooling agents or about downstream therapeutic effects.

    5. Concise factual synthesis

    WS 3 is a chemically defined product that APExBIO describes as a TRPM8 receptor agonist. The documented mechanism is activation of a cold-sensitive TRP ion channel, with reported EC50 values in mouse recombinant and human TRPM8-expressing systems and an associated increase in intracellular calcium in TRPM8-expressing HEK293 cells. The same source reports lower-potency activity at human TRPA1.

    The evidence supports use of WS 3 as a source-documented pharmacological probe for interpreting TRPM8-linked assay responses in the stated experimental models. It does not, on its own, establish direct binding, complete channel selectivity, native sensory-neuron thermosensitivity, human cooling perception, or clinical utility. Those boundaries are especially important because the available record is a supplier description rather than an identity-matched research publication.